tbuckley/cabot-search huggingface dataset:
CD45 Phosphatase Is Involved in Motility and Development of Hematopoietic Stem and Maturing Cells by the Regulation of Cell Adhesion and Cytokine Signaling.
Authors: Shoham Shivtiel, Isabelle Petit, Abraham Avigdor, Polina Goichberg, Sarit Samira, Alexander Kalinkovich, Orit Kollet, Arnon Nagler, Tsvee Lapidot
Journal: Blood (2004)
Mir-SNP Haplotype in the MicroRNA Maturation Pathway As a Marker of Clinical Outcome in Hodgkin Lymphoma (HL)
Authors: Alfons Navarro, Carmen Muñoz, Anna Gaya, Antonio Martinez, Marina Díaz Beyá, Rut Tejero, Tania Díaz, Gerardo Ferrer, Alvaro Urbano-Ispizua, Mariano Monzó
Journal: Blood (2011)
Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease
Authors: Toshifumi Sugatani, Olga A. Agapova, Yifu Fang, Alycia G. Berman, Joseph M. Wallace, Hartmut H. Malluche, Marie-Claude Faugere, William Smith, Victoria Sung, Keith A. Hruska
Journal: Kidney International (2016)
Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).
Authors: Laura D. Locati, Paolo Bossi, Enrico M. Civelli, Federica Perrone, Cristiana Bergamini, Barbara Cortelazzi, Pasquale Quattrone, Martina Imbimbo, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Luigi Mariani, Davide Tosarello, Camilla Cassani, Alfonso Marchiano', Gabriella Saibene, Silvana Pilotti, Lisa F. Licitra
Journal: Journal of Clinical Oncology (2013)

6020 Background: Palliative chemotherapy is the standard of care for RMSGCs. However its activity is usually poor especially in adenoid cystic carcinoma (ACC), while in histotypes other than ACC (non ACC) the response, if any, is of short duration. Some preclinical and clinical evidence suggest a rationale for the employment of anti-angiogenetic agents in RMSGCs, such as sorafenib. Methods: Subjects withproven RMSGC not amenable to surgery and/or radiotherapy were enrolled to receive sorafenib at 400 mg BID q28 days until disease progression, unacceptable toxicity or consent withdrawal. Primary endpoint was response rate (RR) (CR+PR) according to RECIST; secondary objectives included RR according to CHOI criteria, disease control rate (DCR) and toxicity. 37 subjects were required to test the null hypothesis that RR will be ≤ 5% versus the alternative that RR ≥ 20% within a two stage Simon design. At least 4 responders were necessary to reject the null hypothesis. Results: 19 ACC and 18 non ACC subjects were accrued from September 2010 to September 2012. 21 patients had received at least one chemotherapy regimen for RMSGC. Overall 6 PRs according to RECIST were recorded corresponding to a RR of 16% (95% CI 6,2-32,0) (11% in ACC and 22% in non ACC). PR according to CHOI was observed in 10 cases (of which only 2 were concordant with RECIST); no response was reported in 15 cases while CHOI response was not evaluable in 12 patients. A dramatic necrotic evolution of the disease, which resulted in cavitation of metastatic lesions in one case, was observed in two patients with mucoepidermoid cancer (MEC). SD was 57% lasting a median of 7 months (range 2-15+ months). At a median follow up of 10 months (range 3-28+ months): 5 patients are still receiving sorafenib; 15 are no longer being treated and 17 have died. AEs were generally consistent with previous sorafenib studies, except for one G5 toxicity due to meningitis (probably related to necrosis of a local relapse) and one G3 aspergillus abscess. Conclusions: Sorafenib is the first anti-angiogenetic agent to demonstrate some activity in RMSGCs, particularly in MEC. Molecular analyses, typifying MEC and ACC are ongoing. Clinical trial information: NCT01703455.
In Vitro Exflagellation of<i>Plasmodium vivax</i>
Authors: Brenno Balestra, Luisa Carnino
Journal: New England Journal of Medicine (2016)

After recently arriving in Switzerland seeking asylum, a 24-year-old man from Eritrea presented to the ED with recurrent fevers. He reported having had fevers approximately every 2 months for the previous 3 years.
Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma
Authors: Arghya Ray, Deepika Sharma DAS, Yan Song, Dharminder Chauhan, Kenneth C Anderson
Journal: Blood (2015)
Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights
Authors: L. Porcelli, R.M. Iacobazzi, O. Brunetti, M. Signorile, S. Delcuratolo, G. Massiah, P. Cito, N. Silvestris, A. Azzariti
Journal: Annals of Oncology (2015)
Previous Interferon Treatment Failure is Associated with Avery Low Chance of Response to Peginterferon Retreatment in HBeAg-Positive Chronic Hepatitis B: Pooled Analysis of Two Randomized Trials
Authors: M.J. Sonneveld, J. Cheng, Q. Xie, B. Hansen, J. Hou, F. Tabak, H.L. Janssen
Journal: Journal of Hepatology (2016)
Ursodeoxycholic Acid in Advanced Polycystic Liver Disease: A Multicenter Randomized Controlled Phase 2 Trial (Cursor)
Authors: H.M.A. D’Agnolo, W. Kievit, B. Takkenberg, I. Riano, L. Bujanda, M. Neijenhuis, E. Brunenberg, U. Beuers, J. Banales, J. Drenth
Journal: Journal of Hepatology (2016)
Targeting of MIR-518D Reduces Chemoresistance in Hepatocellular Carcinoma Cell Lines
Authors: D.F. Ramos, P.F. Tussy, M.J. Perugorria, J.M. Bañales, Ó. Briz, E. Herráez, J.J.G. Marín, J.M. Mato, M.L.M. Chantar
Journal: Journal of Hepatology (2016)
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Authors: Manuela Salvucci, Maximilian L. Würstle, Clare Morgan, Sarah Curry, Mattia Cremona, Andreas U. Lindner, Orna Bacon, Alexa J. Resler, Áine C. Murphy, Robert O'Byrne, Lorna Flanagan, Sonali Dasgupta, Nadege Rice, Camilla Pilati, Elisabeth Zink, Lisa M. Schöller, Sinead Toomey, Mark Lawler, Patrick G. Johnston, Richard Wilson, Sophie Camilleri-Broët, Manuel Salto-Tellez, Deborah A. McNamara, Elaine W. Kay, Pierre Laurent-Puig, Sandra Van Schaeybroeck, Bryan T. Hennessy, Daniel B. Longley, Markus Rehm, Jochen H.M. Prehn
Journal: Clinical Cancer Research (2016)

Apoptosis is essential for chemotherapy responses. In this discovery and validation study, we evaluated the suitability of a mathematical model of apoptosis execution (APOPTO-CELL) as a stand-alone signature and as a constituent of further refined prognostic stratification tools.
Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.
Authors: G. Von Minckwitz, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann, J. U. Blohmer, S. D. Costa, J. Hilfrich, C. Jackisch, B. Gerber, A. Du Bois, J. B. Huober, C. A. Hanusch, G. E. Konecny, W. Fett, E. Stickeler, N. Harbeck, K. Mehta, S. Loibl, M. Untch
Journal: Journal of Clinical Oncology (2011)

1028 Background: Definition of pCR and its prognostic value in breast cancer subgroups has not been studied formally. We therefore correlated pCR and survival using our meta-database of 7 German neoadjuvant trials using anthracyclines, taxanes regimen with or without trastuzumab. Methods: 6,377 Pts with operable or locally advanced, non-metastatic breast cancer from GeparDuo (N=907), GeparTrio-Pilot (N=285), GeparTrio (N=2072); GeparQuattro (N=1495). AGO 1 (N=666), Prepare (N=733) and Techno (N=217) were analyzed. Pts were 50+ years in 50.6%, had cT1/2 tumors in 71.2%, cN- disease in 49.9%, lobular histology in 13.6%, G1/2 in 59.9%, ER pos in 62.4%, PR pos in 53.7%, HER2 neg in 69.8%. 1466 (23%) relapses and 775 (12.2%) deaths were observed during a median follow up of 42 (0−127) months. Log rank tests and Cox regression (CR) analysis were performed. Results: DFS was superior in Pts with ypT0/ypN0 (=pCR) (N=955) compared to Pts with ypTis/ypN0 (N=309) (p=0.001) and to Pts with ypT≥1 or ypN+ residual disease (N=5112) (p<0.0001). ypT and ypN stage separated multiple distinct prognostic subgroups (p<0.0001). Histologic breast tumor regression (Sinn) failed to provide further information (CR: p=0.28). pCR was prognostic for DFS in the following subgroups: ductal (p<0.0001), non-ductal/non-lobular types (p<0.002), G2 (p=0.013), G3 (p<0.0001), ER− (p<0.0001); ER+/G3 (p=0.003), PgR− (p<0.0001), ER−/PgR+ (p=0.008); ER−/PgR− (p<0.0001), HER2+ (p<0.0001), HER2− (p<0.0001), ER+/HER2− (p=0.04), Rec+/HER2− (p=0.025); Rec−/HER2− (p<0.0001), Rec−/HER2+ (p<0.0001), but not in the following subgroups: lobular (p=0.7), G1 (p=0.8), ER+ (p=0.14), ER+/G1 (p=0.8), ER+/G2 (p=0.9), PgR+ (p=0.08), ER+/PgR+ (p=0.3), ER+/PgR− (p=0.09), ER+/HER2+ (p=0.9), Rec+/HER2+ (p=0.445). Similar results were obtained for overall survival. Conclusions: pCR should be conservatively defined as ypT0ypN0 excluding DCIS. ypT and ypN stages, but not regression grades provide additional prognostic information. pCR strongly correlates with DFS in higher risk groups, but not in luminal A-like and ER+/HER2+ tumors.
T-bet inhibits innate lymphoid cell–mediated eosinophilic airway inflammation by suppressing IL-9 production
Authors: Ayako Matsuki, Hiroaki Takatori, Sohei Makita, Masaya Yokota, Tomohiro Tamachi, Akira Suto, Kotaro Suzuki, Koichi Hirose, Hiroshi Nakajima
Journal: Journal of Allergy and Clinical Immunology (2016)
Belgian rheumatologists' perceptions on eligibility of RA patients for anti-TNF treatment
Authors: Patrick Verschueren, Johan Vanhoof, Hubert Berghs, Johan Praet, Greet Esselens, Simonne Lens, Jean-Pierre Dufour, Marc Vandenberghe, Xavier Van Mullem, Rene Westhovens, Piet Geusens
Journal: Annals of the Rheumatic Diseases (2007)
P1336 : Treatment of type 1 hepatorenal syndrome with terlipressin infusion adjusted according to hemodynamic response. The ameliorate study
Authors: P. Huelin, E. Rodriguez, M. Poca, M. Martin-Llahi, C. Elia, R. Moreira, C. Solè, I. Cirera, J. Sanchez, V. Vargas, G. Soriano, V. Arroyo, E. Sola, P. Gines
Journal: Journal of Hepatology (2015)
Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study
Authors: Pier Luigi Zinzani, Stefano Luminari, Francesco Merli, Emanuela Anna Pesce, Stephane Chauvie, Cinzia Pellegrini, Luigi Marcheselli, Isabella Capodanno, Fiorella Ilariucci, Massimiliano Salati, Lisa Argnani, Massimo Federico
Journal: Blood (2014)
Non-Invasive Assessment of Steatosis and Liver Fibrosis in Overweight and Obese Patients
Authors: T. Broquetas, M. Puigvehí, S. Coll, M. García-Retortillo, N. Cañete, R. Fernández, B. Cabrero, M.D. Giménez, J. Gimeno, F. Bory, J. Pedro-Botet, R. Solà, J.A. Carrión
Journal: Journal of Hepatology (2016)
Biomaterials for Abrogating Metastasis: Bridging the Gap between Basic and Translational Research
Authors: João Conde, Noam Shomron, Natalie Artzi
Journal: Advanced Healthcare Materials (2016)

Herein lies the issue of how to best approach cancer metastasis therapeutics in a focused, directed and efficacious manner. The lack of standardized means to efficiently deliver therapeutic cargo to metastatic sites calls for a paradigm shift in the way we view and treat metastasis. It is crucial to leverage the potential of nanomedicine to differentially combat cancer spread at each stage of the disease (primary tumor growth and formation of metastases) while considering the optimal administration route. We propose to implement three possible strategies to treat cancer as a function of disease type and state, while leveraging the advancement in materials design and in particular nanotechnology: (1) local primary tumor abrogation; (2) primary tumor re‐programming to prevent metastasis; and (3) combination (local and systemic) therapy when metastasis has already transpired. Herein, we highlight potential means to bridge the gap between basic and translational research as related to metastasis therapy.
Circulating Microparticles Correlate with Severity of Alcoholic Hepatitis, Predict Early Non-Response to Corticosteroid Therapy and Trigger Sterile Inflammation
Authors: S. Sukriti, J.S. Maras, S. Sharma, S. Das, M. Premkumar, M.S. Hussain, D. Kumar, G. Kumar, S. Shastry, A. Choudhary, N. Trehanpati, S.K. Sarin
Journal: Journal of Hepatology (2016)
Effect of high-pressure homogenization on stability of emulsions containing zein and pectin
Authors: Maneerat Juttulapa, Suchada Piriyaprasarth, Hirofumi Takeuchi, Pornsak Sriamornsak
Journal: Asian Journal of Pharmaceutical Sciences (2016)

The aim of this study was to investigate the effect of high-pressure homogenization on the droplet size and physical stability of different formulations of pectin–zein stabilized rice bran oil emulsions. The obtained emulsions, both before and after passing through high-pressure homogenizer, were subjected to stability test under environmental stress conditions, that is, temperature cycling at 4 °C/40 °C for 6 cycles and centrifugal test at 3000 rpm for 10 min. Applying high-pressure homogenization after mechanical homogenization caused only a small additional decrease in emulsion droplet size. The droplet size of emulsions was influenced by the type of pectin used; emulsions using high methoxy pectin (HMP) were smaller than that using low methoxy pectin (LMP). This is due to a greater emulsifying property of HMP than LMP. The emulsions stabilized by HMP–zein showed good physical stability with lower percent creaming index than those using LMP, both before and after passing through high-pressure homogenizer. The stability of emulsions after passing through high-pressure homogenizer was slightly higher when using higher zein concentration, resulting from stronger pectin–zein complexes that could rearrange and adsorb onto the emulsion droplets.
Albi Grade vs. Child-Pugh Grade as a Grading System for Liver Function in Patients with Hepatocellular Carcinoma
Authors: Y.K. Jung, S.K. Na, S.J. Suh, H.J. Yim, S.Y. Kim, J.J. Hyun, S.W. Jung, J.S. Koo, J.H. Kim, Y.S. Seo, J.E. Yeon, S.W. Lee, K.S. Byun, S.H. Um
Journal: Journal of Hepatology (2016)
The Nexus Between Nutrition and Early Childhood Development
Authors: Harold Alderman, Lia Fernald
Journal: Annual Review of Nutrition (2017)

This article looks at both nutrition and early childhood stimulation interventions as part of an integrated life cycle approach to development. We build on recent systematic reviews of child development, which are comprehensive in regard to what is currently known about outcomes reported in key studies. We then focus particularly on implementation, scaling, and economic returns, drawing mainly on experience in low- and middle-income countries where undernutrition and poor child development remain significant public health challenges with implications across the life course.
Correlation of Mutations within HDV-Protein with HLA Backgrounds of Patients Leads to Identification of Novel CD8 T Cell Epitopes
Authors: H. Karimzadeh, B. Budeus, A. Kosinska, T. Bauer, A. Heinold, D. Hoffmann, U. Protzer, M. Roggendorf
Journal: Journal of Hepatology (2016)
Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424–1430
Authors: Shahnam Sharif, Yolanda van der Graaf, Hendrik M. Nathoe, Harold W. de Valk, Frank L.J. Visseren, Jan Westerink
Journal: Diabetes Care (2016)

We appreciate the thoughtful comments and suggestion by Aryan et al. (1) on our recent article on HDL cholesterol (HDL-c) as a residual risk factor for vascular events and all-cause mortality in patients with type 2 diabetes (T2D) (2). The findings of our study in the Second Manifestations of ARTerial disease (SMART) cohort showed that higher HDL-c is related to an unexpected higher risk of cardiovascular events (hazard ratio [HR] 1.10, 95% CI 1.07–1.21) and all-cause mortality (HR 1.14, 95% CI 1.07–1.21) in patients with very low levels of LDL cholesterol (LDL-c) (<2.0 mmol/L). In light of the findings in an ongoing cohort of 2,607 Iranian patients with T2D, Aryan et al. (1) suggest that this unexpected finding can be ascribed to chronic systemic inflammatory status, as they found that higher HDL-c was related to a lower risk of …
Long-term safety and efficacy of autologous bone marrow-derived stem cell transfer after acute myocardial infarction
Authors: Stefan Janssens, Jan Bogaert, Christophe Dubois, Johan Van Cleemput, Koen Theunissen, Maria Kalantzis, Peter Sinnaeve, Walter Desmet, Ann Belmans, Marc Boogaerts, Frank Rademakers, Frans Van de Wert
Journal: Circulation (2006)
Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264–270
Authors: Michael R. Rickels, Katrina J. Ruedy, Nicole C. Foster, Claude A. Piché, Hélène Dulude, Jennifer L. Sherr, William V. Tamborlane, Kathleen E. Bethin, Linda A. DiMeglio, R. Paul Wadwa, Andrew J. Ahmann, Michael J. Haller, Brandon M. Nathan, Santica M. Marcovina, Emmanouil Rampakakis, Linyan Meng, Roy W. Beck
Journal: Diabetes Care (2016)

Rickels et al. (1) report the results of a randomized crossover noninferiority study, making the firm assertion that intranasal glucagon was highly effective in treating insulin-induced hypoglycemia in type 1 diabetes. Unfortunately, the methods described in their article fail to support such a strong claim. We have several concerns about their ambitious conclusion. First, because of the controlled and artificial environment, this was not an effectiveness but an efficacy trial. Testing effectiveness requires carrying out the comparison in a “real-world setting” of severe hypoglycemia. Second, the design of the study does not seem appropriate considering that the intention was to prove intranasal glucagon was clinically equivalent to …
HCC Derived Circulating Microparticles Detect Hepatocellular Carcinoma and Differ from Other Cancer Related Microparticles
Authors: H. Julich, M. Krawczyk, A. Willms, M. Casper, M. Glanemann, R. Schwab, I. Richardsen, S. Schaaf, C. Geis, M. Krawczyk, F. Lammert, V. Lukacs-Kornek, D. Schuppan, M. Kornek
Journal: Journal of Hepatology (2016)
Redirected CD4+ T Cells towards HLA Class I-Restricted WT1 Epitope Successfully Display Multifactorial Helper Function for the Enhancement of Antileukemia Efficacy Mediated by Redirected T-Cell Based Immunocelltherapy.
Authors: Yukihiro Miyazaki, Hiroshi Fujiwara, Toshiki Ochi, Sachiko Okamoto, Hiroaki Asai, Junichi Mineno, Miwako Narita, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa
Journal: Blood (2012)
Better Survival in Patients with Hepatitis E Virus C.F. to Other Acute Insults Causing Acute-on-Chronic Liver Failure (ACLF) – APASL-ACLF Research Consortium (AARC) Database
Authors: A. Goel, C.E. Eapen, A. Choudhary, M.K. Sharma, R. Maiwall, M. Al Mahtab, Y.K. Chawla, S.-S. Tan, Q. Ning, H. Devarbhavi, D.N. Amrapurkar, C.W. Kim, S.S. Hamid, A.S. Butt, H. Ghazinyan, Z. Duan, C. Yu, A. Sood, G.H. Lee, Z. Abbas, G. Shiha, L.A. Lesmana, D.A. Payawal, A. Kadir Dokmeci, M.F. Yuen, G.K. Lau, Md.F. Karim, J.D. Sollano, S.K. Sarin
Journal: Journal of Hepatology (2016)
Overall survival (OS) and time to failure (TTF) associated with anti-myeloma therapy in a U.S. managed-care population.
Authors: L. Ma, K. L. Stevinson, T. A. Burke, S. Kumar
Journal: Journal of Clinical Oncology (2010)

e18505 Background: Studies suggest that survival of patients with myeloma (MM) has improved in the last decade due to increased availability of new therapies such as bortezomib (BOR), IMiDs and autologous stem cell transplant (SCT). There are few data on outcomes since their introduction into routine clinical practice. This study's objective was to assess OS and TTF among patients diagnosed with MM before or after the 2003 US approval of BOR. Methods: This was a retrospective cohort study using enrollment and claims data from a commercial U.S. managed care organization with an annual enrollment ranging from 9-15 million. Subjects ≥ 18 years with treated MM, newly diagnosed between 7/1/2000 and 12/31/2007, were identified by ICD9-CM diagnosis code and followed from diagnosis until end of continuous enrollment or 12/31/2008. Anti-MM regimens were defined as sequentially administered groups of anti-neoplastic drugs or SCT procedure(s) identified from claims. To evaluate OS, patients with at least one anti-MM regimen were matched to the Social Security Death Master File (SSDMF) through 2/2009 and the National Death Index (NDI) through 12/2007 and patient-level results were consolidated. OS (time from MM diagnosis to death) and TTF by regimen (time to the start of new regimen or to death), were summarized using the Kaplan-Meier method and further analyzed using Cox proportional hazards model to compare pre and post 6/2003 periods. Results: 2,210 patients with a mean age of 59.9 years were identified. 44.5 % were female. Death records were found in SSDMF or NDI for 380/650 (58.5%) diagnosed prior to and 510/1560 (32.7%) after 6/2003. The median OS for the cohort was 6.1 years. The risk of death for patients diagnosed after 6/2003 was reduced relative to diagnosis before 6/2003 (HR=0.76, 95% CI: 0.66, 0.87; p < 0.0001). Median TTF decreased across lines of therapy 1-6 (250, 228, 215, 125, 163, and 101 days respectively). TTF, controlling for line of therapy, was similar pre- and post-2003. Conclusions: The risk for death associated with treated MM diagnosed post 6/2003 was significantly reduced compared to pre-2003. The introduction of new MM therapies is associated with improved OS in this US commercial insurance population. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck Merck Merck Merck
Liver Transplantation in Hungarian Wilson’S Disease Patients, 1998–2015
Authors: D. Németh, A. Folhoffer, S. László, L. Kóbori, D. Görög, I. Fehérvári, J. Fazakas, Z. Gerlei, Z. Máthé, F. Szalay
Journal: Journal of Hepatology (2016)
Impact of Hepatopulmonary Syndrome on Prognosis after Liver Transplantation
Authors: E. Dueñas, R. Rota, J. Ribas, A. Ruiz - Majoral, E. González - Vilatarsana, A. Cachero, K. Serra, C. Baliellas, J. Fabregat, X. Xiol, J. Castellote
Journal: Journal of Hepatology (2016)
STUDIES ON THE BACTERIOPHAGE OF D'HERELLE
Authors: Ralph S. Muckenfuss
Journal: The Journal of Experimental Medicine (1928)

1. The phenomenon of phage production by one bacterial culture for another of different sort has been reproduced experimentally. 2. This phenomenon results from phage carried with the culture, and not from the spontaneous appearance of phage in a culture previously free from it. 3. Animals immunized against the lysogenic bacteria may develop antibodies that neutralize the phage carried. 4. The development of neutralizing antibodies on immunization with a bacterial culture is evidence of the presence of bacteriophage in the culture. 5. The failure of such antibodies to appear on immunization with bacteria does not necessarily indicate that bacteriophage is not present.
Abstract 2817: Allelic Expression Imbalance Analysis in Heart Failure Samples Finds Novel cis-acting Alleles in ACE and SOD2
Authors: Andrew D Johnson, Audrey C Papp, Amanda Lesinski, Philip Binkley, Wolfgang Sadee
Journal: Circulation (2006)

INTRODUCTION: Despite identification of probable candidate genes, elucidation of the genetic elements that influence human susceptibility to cardiovascular disease is elusive. Heterozygous SNPs in ...
Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras
Authors: S. Susser, J. Dietz, M. Barak, B. Schlevogt, R. Daniel, V. Piazzolla, S. Passmann, M. Cornberg, E. Zuckerman, A. Mangia, S. Zeuzem, C. Sarrazin
Journal: Journal of Hepatology (2016)
Impact of Genetic Polymorphisms in the SCARB1 Gene on Hepatitis C Virus
Authors: S. Westhaus, M. Deest, F. Stanke, D. Heckl, A. Schambach, M.P. Manns, T. Berg, C. Sarrazin, S. Ciesek, T. von Hahn
Journal: Journal of Hepatology (2016)